Clinical trials: Pirtobrutinib, active
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by…
- Trial name
- NCT07685717
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jennifer Woyach
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- NCT05677919
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Relapsed and Refractory DLBCL
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a prospective, single arm trial in patients with ≥ 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and…
- Trial name
- NCT07122609
- Testing
- Pirtobrutinib, R-GemOx, Polatuzumab Vedotin
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Richter Syndrome
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
This single-arm, multicenter, open-label phase II trial evaluates the efficacy and safety of rituximab + pirtobrutinib + lisaftoclax + liposomal mitoxantrone in adults with CLL-transformed Richter syndrome (CLL-RS).
- Trial name
- RPLM-RS (NCT07831395)
- Testing
- Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib
- Where
- 6 sites in China
- Volunteers
- 23 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Waldenstrom Macroglobulinemia
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
- Trial name
- MPOWER (NCT07548450)
- Testing
- Pirtobrutinib, Mosunetuzumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Richter Transformation
A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
The aim of the trial is to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation
- Trial name
- CLLRT2 (NCT07917780)
- Testing
- Epcoritamab, Pirtobrutinib, Cyclophosphamide
- Where
- 12 sites in Australia, Austria and 3 more
- Volunteers
- 116 people
- Sponsor
- German CLL Study Group
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell…
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT05990465
- Testing
- Pirtobrutinib, LV20.19 CAR T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Pirtobrutinib, Immunochemotherapy
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and…
- Conditions
- Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
- Trial name
- NCT07812493
- Testing
- pirtobrutinib+MTX+immunolchemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Pengpeng Xu
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with…
- Trial name
- NCT06466122
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kerry Rogers
Mantle Cell Lymphoma (MCL)
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
This prospective, open-label, phase 2 study will evaluate the efficacy and safety of lisaftoclax in combination with pirtobrutinib in adults with relapsed or refractory mantle cell lymphoma following failure of prior BTK-targeted…
- Trial name
- NCT07684950
- Testing
- Lisaftoclax, Pirtobrutinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Henan Cancer Hospital
Lymphoma, Mantle-Cell
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by…
- Trial name
- BRUIN-MCL-321 (NCT04662255)
- Testing
- Pirtobrutinib, Ibrutinib, Acalabrutinib
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 500 people
- Sponsor
- Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
- Trial name
- NCT06333262
- Testing
- Pirtobrutinib, Obinutuzumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Inhye Ahn
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT07218341
- Testing
- Pirtobrutinib, Idelalisib
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
PCNSL, Primary Central Nervous System Lymphoma
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
The goal of this clinical trial is to evaluate the efficacy and safety of a four-drug combination regimen as first-line treatment for adults aged 18 years and older with newly diagnosed primary central nervous system lymphoma…
- Trial name
- PRIME-PCNSL (NCT07350850)
- Testing
- Pirtobrutinib, Sintilimab, Rituximab, Methotrexate, Standard of Care (Investigator Selected)
- Where
- 4 sites in China
- Volunteers
- 77 people
- Sponsor
- Tongji Hospital
DLBCL - Diffuse Large B Cell Lymphoma
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of…
- Trial name
- NCT07255963
- Testing
- Pirtobrutinib, Lisaftoclax, Rituximab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
- Trial name
- NCT06967610
- Testing
- Pirtobrutinib, Venetoclax, Obinutuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Trial name
- NCT06973187
- Testing
- Tacabrutideg, Pirtobrutinib
- Where
- 217 sites in United States, Argentina and 22 more
- Volunteers
- 500 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA.
- Trial name
- NCT06876662
- Testing
- Pirtobrutinib
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 279 people
- Sponsor
- Eli Lilly and Company
DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
- Trial name
- NCT07744737
- Testing
- Pirtobrutinib plus R-CHOP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Changzhou No.2 People's Hospital
DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
This is a single-arm, open-label, multicenter clinical study evaluating the efficacy and safety of pirtobrutinib combined with Pola-R-CHP in previously untreated Non-GCB DLBCL.
- Trial name
- NCT07744724
- Testing
- Pirtobrutinib+Pola-R-CHP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Changzhou No.2 People's Hospital